Eterna Therapeutics Inc (NASDAQ:ERNA)’s traded shares stood at 0.33 million during the last session, with the company’s beta value hitting 4.30. At the close of trading, the stock’s price was $0.25, to imply a decrease of -10.63% or -$0.03 in intraday trading. The ERNA share’s 52-week high remains $2.62, putting it -948.0% down since that peak but still an impressive 12.0% since price per share fell to its 52-week low of $0.22. The company has a valuation of $12.99M, with an average of 0.43 million shares in intraday trading volume over the past 10 days and average of 734.59K shares over the past 3 months.

Eterna Therapeutics Inc (NASDAQ:ERNA) trade information

After registering a -10.63% downside in the last session, Eterna Therapeutics Inc (ERNA) has traded red over the past five days. The 5-day price performance for the stock is 2.22%, and -45.95% over 30 days. With these gigs, the year-to-date price performance is -85.91%. Short interest in Eterna Therapeutics Inc (NASDAQ:ERNA) saw shorts transact 44458.0 shares and set a 1.07 days time to cover.

ERNA Dividends

Eterna Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Eterna Therapeutics Inc (NASDAQ:ERNA)’s Major holders

Eterna Therapeutics Inc insiders hold 336.35% of total outstanding shares, with institutional holders owning 11.00% of the shares at -4.65% float percentage. In total, 11.00% institutions holds shares in the company.